Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2026-02-02 @ 3:03 AM
Study NCT ID:
NCT00825734
Status:
COMPLETED
Last Update Posted:
2014-12-22
First Post:
2009-01-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Sponsor:
SCRI Development Innovations, LLC
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCRI BRE 138
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None